Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.625 4.03% 16.125 359,170 09:39:17
Bid Price Offer Price High Price Low Price Open Price
15.75 16.50 16.25 15.50 15.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -6.71 -1.45 101
Last Trade Time Trade Type Trade Size Trade Price Currency
10:46:00 O 3,696 15.905 GBX

Scancell (SCLP) Latest News

More Scancell News
Scancell Takeover Rumours

Scancell (SCLP) Discussions and Chat

Scancell Forums and Chat

Date Time Title Posts
25/9/202011:00Using immunology to fight cancer.32,511
22/9/202009:26Scancell short thread6
25/4/202013:41Could this be the end of cancer?773
16/8/201408:47Using immunology to fight cancer (LTH W/O Rose Tints - Free Speech Thread)161

Add a New Thread

Scancell (SCLP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Scancell trades in real-time

Scancell (SCLP) Top Chat Posts

Scancell Daily Update: Scancell Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 15.50p.
Scancell Holdings Plc has a 4 week average price of 8.15p and a 12 week average price of 5.15p.
The 1 year high share price is 17.75p while the 1 year low share price is currently 4.35p.
There are currently 629,127,092 shares in issue and the average daily traded volume is 2,953,309 shares. The market capitalisation of Scancell Holdings Plc is £101,446,743.59.
emptyend: .....they are totally worthless unless he pays the company 8.15p per share. End of.It is part of overall compensation - and one which totally aligns his economic interest with shareholders at all share prices over 8.15p. He gets no more of a return, nor less.Under 8.15p they are totally worthless.......and they were granted when the share price was well under 8.15p.cheerio
inanaco: Gazza The other day you posted about the history of dilution in Scancell ... with some of the funds raised at a discount to share price causing dilution in the value of your holding .. but the reverse of that is true, that money has been spent on taking the products to clinic but as yet no value attributed .. because the share price is still sitting at the share price scancell floated at that point it only had Scib1 entering the clinic .. so if you think that money has been spent wisely .. then surely the re-rate from that investment over the years will apply which is why i asked ONW about the NAV and why he did not want to answer, he thought bamboozling the BB with various functions would hide the effects of Dilution of the IP from the nonsense that the share price got diluted .. anyway .... so that is my last post on the subject Best of luck with your investment
gooosed: ""Healthcare names have dominated the AIM market since the coronavirus pandemic broke out. Companies such as Novacyt SA (LON:NCYT), Synairgen PLC (LON:SNG) and Genedrive PLC (LON:GDR) have been the three top performers in the year to date, with share prices rocketing 2,455%, 852% and 610% respectively. Experts say that COVID-19 has sparked change in a sector long gone under the radar. Traditionally, small UK players have been struggling with low cash levels, hindering both their programmes and the chance to do promotional activity to raise more funds. The British regulatory pathway is much slower compared to the relatively speedy US bureaucracy, while an underfunded NHS is keeping demand for new technologies very low. For biotech projects especially, investors have looked at UK companies as having less potential for success compared to US rivals with much more cash to splurge. “Coronavirus has made us take a fresh look at the sector… The competitive landscape seems to have changed,” said Emma Ulker, an analyst at Proactive. “It has highlighted the value of the sector and I’m really impressed by the way some of the companies have adapted very quickly to produce or to adapt their products towards finding a solution or a diagnostic.” Graham Doyle, an analyst at Liberum, adds the pandemic has been especially favourable for the diagnostics sectors. Top risers Novacyt and Genedrive have focused on swab tests, while Avacta Group PLC (LON:AVCT) has used its Affimer protein to develop reagents for testing. EKF Diagnostics Holdings PLC (LON:EKF) has been another strong riser, thanks to its sample collection device that allows safe handling and transport. “The question is how much of the performance is on the fundamentals of the business and how much is based on trading flows and a degree of retail flows,” Doyle wonders. In the therapies space, most companies have been re-purposing existing projects to tackle the pandemic. Synairgen switched its chronic obstructive pulmonary disease (COPD) candidate SNG001 to coronavirus treatment, while Tiziana Life Sciences PLC (LON:TILS) has filed a patent to use a combination of nanoparticle-Actinomycin D, an existing treatment for infectious diseases, and its antibody anti-IL-6R. Elsewhere, e-Therapeutics PLC (LON:ETX) has re-jigged an existing platform to test approved and known drugs, both alone and as combinations, for Covid-19 treatment. With share prices rocketing in the past few months, many names have exploited the momentum in share price to raise new cash at a lower dilution."
tosh123: Yet more contradictory rubbish from the village idiot ... " the share price is not the Holy Grail ......... indeed if it was why would any one buy to sit still" .... Answer = Sitting still after buying would be a welcome development for you ineptico. Far from sitting still, you've managed to lose 90% of your investment so can only wish for such an achievement as " sitting still ". Also, share price IS the holy grail. Unlike you, most ( if not all ) investors do so to make profit ( a concept that will be foreign to you ), so YES, share price is the holy grail. " this is a capital appreciation share ......... it will happen, if Trinity are right 15.7p before covid results "... Answer = 15.70p !!!! What happened to the much publicised £8 ?. Surely, the words " we are all minted " cant be attributed to a share price of 15.7p, especially when your average, and that of those who stupidly listened to you, is way above 15.7p. This is NOT a Capital appreciation share, its just the opposite ! Once again you mate a total ar5e of yourself with such nonsense. How can an investment of 45p, which is now worth 6.5p, be classed as a capital appreciation ??? You're Bonkers. Basically, you have just rubbished your own posts ( yet again ). You just continually make a fool of yourself... Amusing ... People just laugh at you.
10acious: Agree Bermuda. But it will pale into insignificance when compared with SCLP share price performance.
gazza: You can't predict sentiment. As an investor, you must ignore sentiment and look for the true (fiscal) value. A trader may well capitalise on sentiment for short term gain. I value SCLP (today) at 17-38p. A current share price of 7p indicates sentiment is poor. Not surprising given the delayed start to the trial, the IND hold up in the US, no word of progress on SCIB2, no word on progress of the BioNtech tie up, manufacturing issues with Modi, cash running out in a matter of month.... Yes, sentiment is poor but that does not change the underlying VALUE. If there was an RNS about a cash deal, the share price might shoot up to 50p. This would indicate (overly) good sentiment. Again, it wouldn't change the underlying value and you would expect the share price to return to the value range. I'm not sure why you keep writing "share price 7p". We can see that. Do you actually have a point you would like to make?
oldnotwise: I see that LSE are having selected posts removed from their SCLP BB. I'm not certain whether I should say that LSE is:- 1) Having selected posts removed Or 2) LSE is selectively removing posts. Only mention it because Crackin posted a list of SCLP share prices earlier (which naturally displayed a less than Bullish progression for Scancell - "The Actuality"), which received a good number of "recs" and that post was removed for no apparent reason. Sadly it looks like the Censorship on LSE has survived the start of the new decade. It's a crying shame that for some reason nothing that conflicts with the wild optimism spouted over there seems to be allowed to remain for very long. That reminds me why I cancelled my account there.... completely rose coloured posts anly allowed. Painful... Happy New Year all LOL! AIMO ATB
ivyspivey: Wish it was Inanaco who had resigned and stayed away rather than a valued and well liked poster like Lozan. After the hell of a beating Inanaco and his chums in Parliament took last night you think he would be licking his wounds. The question is which will be delayed longer Brexit is the start of the Combo trial. The only thing we do know is Inanaco will get it wrong whether it is him saying that SCLP have NOT delayed the start of the SCIB 1 Combo trial or his original claim that Brexit was nailed on 31st March. Great to see the SCLP share price rise today in spite of the endless lying by likes of Inanaco and his carpetbagger mates of the IRG
gazza: Inan, you said: "Currency movements which are actually inverse to the stock market £/$ pair" OK, let's work this out. If you are talking about SCLP share price then.. Has gone from 60p to 6p Inverse would be 6p to 60p (x 10 up) £/E was 1.00/1.20 so applying your inverse stock price principle 1 GBP would now be 12 EUR. If that were the case, I'd have bought the house next door to Loz and would now be sharing a 1664 whilst discussing the grass length.
tosh123: Somewhat ironic that the caped crusader ridicules the holders of VAL by saying that he warned them of the share price collapse , when HE himself was warned by many of us that the SCLP share price was going to crash, but still bought more at 45p. The idiot is pointing a finger at people who have done EXACTLY the same as he is guilty of... What a plank.
Scancell share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200925 10:15:34